EMA Confirms 'No Good' Stance On Omega-3 Drugs
Executive Summary
The terms of the marketing authorizations for oral-use omega-3 fatty acid-containing medicines in the EU will have to updated to reflect the fact that they should no longer be used for secondary prevention after myocardial infarction.